肝胆期MRI引导射频消融治疗平扫MRI不可见的小肝细胞癌
本研究纳入53例肝硬化患者的小肝细胞癌病灶,这些病灶在非增强MRI上不可见,采用肝胆期MRI引导经皮射频消融。技术成功率为98%(51例,55个肿瘤),无 major 并发症,随访(26.2±22.4月)未见局部肿瘤进展或复发。作者认为肝胆期MRI引导消融是治疗MR隐匿性小肝癌结节可行、有效且安全的方法。
要点
- 平扫MRI不可见的小肝癌病灶可在肝胆期显示,并作为MRI引导射频消融的靶区。
- 技术成功率98%(51例,55个肿瘤),以完全消融且安全边缘达5 mm为定义。
- 平均肿瘤直径9.7±1.9 mm,平均调整穿刺针5±3次,无 major 并发症。
核心结论
- 利用肝胆期进行MRI引导消融,对于其他序列MR隐匿的小肝癌结节,是一种可行、有效且安全的治疗方法。
研究设计与样本
- 单臂可行性研究,纳入53例患者(17例女性,年龄63.6±16.7岁),均为非增强MRI不可见的小肝细胞癌,接受MRI引导经皮射频消融;技术成功定义为完全消融并达到5 mm安全边缘。
关键影像表现/征象
- 所有53例的目标肿瘤在非增强MRI上不可见,但在肝胆期可见。
- 5例在计划成像时发现新肿瘤,其中4例在同一次治疗中处理,1例改变了治疗策略。
- 平均肿瘤直径为9.7±1.9 mm。
- 穿刺针调整次数为5±3次。
诊断标准与关键数值
- 技术成功定义为完全消融并达到5 mm安全边缘,术后成像显示技术成功率为98%(51例,55个肿瘤)。
- 安全性通过手术相关并发症报告评估,未发生 major 并发症。
- 随访成像(26.2±22.4月)显示无局部肿瘤进展或复发。
临床应用与阅片要点
- 对于平扫MRI不可见的小肝癌,可参考肝胆期图像进行靶区定位和MRI引导穿刺。
- 计划成像时可能发现新肿瘤,需在同一次治疗中处理或调整治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: In cirrhotic livers reliable visualization and exact localization of small hepatocellular carcinoma (HCC) can be challenging without adequate contrast enhancement. To investigate the feasibility, technical success rate, and safety of hepatobiliary phase MRI-guided percutaneous radiofrequency ablation (RFA) of small HCCs invisible on precontrast MRI.
METHODS: 53 patients (17f, 63.6 ± 16.7 years), with small HCC that were not visible in non-contrast MRI underwent MRI guided RFA. Feasibility was assessed by analyzing proper identification of the target tumor, tumor delineation during MRI-guided needle positioning and number of needle adjustments required for accurate placement. Technical success was defined as complete ablation with a safety margin of 5 mm. Safety was assessed from reports of procedure-related complications.
RESULTS: In all 53 cases, target tumors were not visible in non-contrast MRI but in the hepatobiliary phase. In 5 cases, planning imaging showed new tumors, which were either treated in the same session (n = 4) or altered the therapeutic approach (n = 1). Mean tumor diameter was 9.7 ± 1.9 mm and the number of needle adjustments was 5 ± 3. Post-ablation imaging showed a technical success rate of 98 % (51 cases, 55 tumors). No major complications occurred. Follow-up imaging (26.2 ± 22.4 month) showed no local tumor progression or recurrence.
CONCLUSIONS: Use of the hepatobiliary phase for MRI-guided ablation of otherwise MR-occult tumors is a feasible approach for an effective and safe treatment of small HCC nodules.
引用
- Ebel S, Busse H, Beeskow A, et al. Hepatobiliary phase MRI-guided radiofrequency ablation of small hepatocellular carcinomas invisible on precontrast MRI. Eur J Radiol. 2025. PMID: 40054338. doi:10.1016/j.ejrad.2025.112026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。